Search

Your search keyword '"Leccia, M. T."' showing total 531 results
Start Over Author "Leccia, M. T."
531 results on '"Leccia, M. T."'

2. Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data☆

Author

Di Filippo, Y., Dalle, S., Mortier, L., Dereure, O., Dalac, S., Dutriaux, C., Leccia, M.-T., Legoupil, D., Saiag, P., Brunet-Possenti, F., Arnnault, J.-P., Maubec, E., Granel-Brocard, F., De Quatrebarbes, J., Aubin, F., Lesimple, T., Beylot-Barry, M., Stoebner, P.-E., Dupuy, A., Stephan, A., Grob, J.-J., Lefevre, W., Oriano, B., Allayous, C., Lebbé, C., and Montaudié, H.

Published
2021
Full Text
View/download PDF

7. HPV vaccination practices among organ transplant recipients in France

Author

de Quatrebarbes, J., primary, Chanal, J., additional, Ducroux, E., additional, Leccia, M.-T., additional, Kanitakis, J., additional, Guegan, S., additional, Dadban, A., additional, Sassolas, B., additional, Deylon, J., additional, Malissen, N., additional, Boukari, F., additional, Du Thanh, A., additional, Boussemart, L., additional, Lebbé, C., additional, and Barete, S., additional

Published
2024
Full Text
View/download PDF

11. Thirty years of promoting sun safety in France: The messages are heard but not followed!

Author

Passeron, T., Lim, H. W., Goh, C. L., Kang, H. Y., Ribeyre, C., Demessant‐Flavigny, A.‐L., Le Floc'h, C., Kerob, D., Krutmann, J., Comte, C., Dreno, B., and Leccia, M. T.

Abstract

A study published in the Journal of the European Academy of Dermatology & Venereology examines the effectiveness of sun safety campaigns in France over the past 30 years. The study found that despite the distribution of messages about sun safety, the number of melanomas and carcinomas in France has increased fivefold. The study surveyed 1000 members of the French population and found that while most respondents were aware of the skin problems caused by too much sun exposure, many still associated a tan with good health and attractiveness. The study suggests that prevention messages should be tailored to specific audiences and emphasizes the importance of dermatologists in educating patients about sun protection. [Extracted from the article]

Published
2024
Full Text
View/download PDF

17. Recommandations pour le diagnostic de prédisposition génétique au mélanome cutané et pour la prise en charge des personnes à risque

Author

Avril, M.-F., Bahadoran, P., Cabaret, O., Caron, O., de la Fouchardière, A., Demenais, F., Desjardins, L., Frébourg, T., Hammel, P., Leccia, M.-T., Lesueur, F., Mahé, E., Martin, L., Maubec, E., Remenieras, A., Richard, S., Robert, C., Soufir, N., Stoppa-Lyonnet, D., Thomas, L., Vabres, P., and Bressac- de Paillerets, B.

Published
2015
Full Text
View/download PDF

18. Traitements locorégionaux de métastase(s) cérébrale(s) chez des patients atteints d’un mélanome cutané métastatique : recommandations nationales françaises

Author

Lubrano, V., Derrey, S., Truc, G., Mirabel, X., Thariat, J., Cupissol, D., Sassolas, B., Combemale, P., Modiano, P., Bedane, C., Dygai-Cochet, I., Lamant, L., Mourrégot, A., Rougé Bugat, M.-È., Siegrist, S., Tiffet, O., Mazeau-Woynar, V., Verdoni, L., Planchamp, F., and Leccia, M.-T.

Published
2014
Full Text
View/download PDF

22. Photodermatoses

Author

Leccia, M. -T., Beani, J. -C., Revuz, Jean, editor, Roujeau, Jean-Claude, editor, Kerdel, Francisco A., editor, and Valeyrie-Allanore, Laurence, editor

Published
2009
Full Text
View/download PDF

31. Traitements systémiques de première et de deuxième lignes des patients atteints d’un mélanome cutané métastatique (hors métastase cérébrale) : Recommandations nationales françaises

Author

Cupissol, D., Sassolas, B., Combemale, P., Modiano, P., Bedane, C., Derrey, S., Dygai-Cochet, I., Lamant, L., Lubrano, V., Mirabel, X., Mourrégot, A., Rougé Bugat, M. -E., Siegrist, S., Thariat, J., Tiffet, O., Truc, G., Verdoni, L., Mazeau-Woynar, V., Planchamp, F., and Leccia, M. T.

Published
2014
Full Text
View/download PDF

36. 1080P HORIZON: Final results from a 5-year ambispective study of 705 patients who initiated pembrolizumab for advanced melanoma in the French early access program

Author

Grob, J.J., primary, Aubin, F., additional, Benmahammed-Bellagha, L., additional, Brunet-Possenti, F., additional, Dereure, O., additional, Dutriaux, C., additional, Duval-Modeste, A-B., additional, Grange, F., additional, Jarvis, C., additional, Kramkimel, N., additional, Leccia, M-T., additional, Machet, L., additional, Meyer, N., additional, Mortier, L., additional, Neidhardt, E-M., additional, Robert, C., additional, Scherrer, E., additional, Spampinato, A., additional, Verdoni, L., additional, and Saiag, P., additional

Published
2021
Full Text
View/download PDF

38. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

Author

Bottomley, A., Coens, C., Mierzynska, J., Blank, C. U., Mandalà, M., Long, G. V., Atkinson, V. G., Dalle, S., Haydon, A. M., Meshcheryakov, A., Khattak, A., Carlino, M. S., Sandhu, S., Puig, S., Ascierto, P. A., Larkin, J., Lorigan, P. C., Rutkowski, P., Schadendorf, D., Koornstra, R., Hernandez-Aya, L., Di Giacomo, A. M., van den Eertwegh, A. J. M., Grob, J. -J., Gutzmer, R., Jamal, R., van Akkooi, A. C. J., Krepler, C., Ibrahim, N., Marreaud, S., Kicinski, M., Suciu, S., Robert, C., Eggermont, A. M. M., EORTC Melanoma Group, Lesimple, T., Maio, M., Linette, G., Mortier, L., Svane, I. M., Schachter, J., Brown, M., Hersey, P., Barrow, C., Kudchadkar, R., Dutriaux, C., Song, X., Quaglino, P., Queirolo, P., Meier, F., Stroyakovskiy, D., Guillot, B., Romero, P. L. O., Bastholt, L., Garbe, C., Grange, F., Mohr, P., Algazi, A., Bechter, O., Hernberg, M., Loquai, C., Meiss, F., Chiarion Sileni, V., Bar-Sela, G., Fitzharris, B., Saiag, P., Arnault, J. -P., Simon, J. -C., Stephens, R., Baurain, J. -F., Lebbe, C., Combemale, P., Dummer, R., Hauschild, A., Parente, P., Yamazaki, N., Milhem, M., Leccia, M. -T., Geoffrois, L., Kretschmer, L., Dunwoodie, E., Walker, J., Lotem, M., Hendler, D., Mackiewicz, A., Sekulovic, L., Dzienis, M., Hospers, G. A. P., Siano, M., Hassel, J., Corrie, P., Passos, M. -J., Levin, M., Hoeller, C., Machet, L., Hallmeyer, S., Waterston, A., Descamps, V., Kiecker, F., Aarts, M., Schmidt, H., Raimundo, A., Nyakas, M., Lacour, J. -P., Berking, C., Ferrucci, P. F., Jameson, M., Kim, K., Yokota, K., Kerger, J., Aubin, F., Groenewegen, G., Kapiteijn, H., Boehncke, W. -H., Utikal, J., Casasola, R., Marshall, E., Ferraresi, V., Richtig, E., Matkovic, S., Inozume, T., Crook, T., Mcneil, C., Kiyohara, Y., Avril, M. -F., Hein, R., Terheyden, P., Nathan, P., Aoi, J., Skytta, T., Jouary, T., Takenouchi, T., Straume, O., Martins, C., Mukhametshina, G., Boehncke, Wolf-Henning, Internal medicine, CCA - Cancer Treatment and quality of life, European Organisation for Research and Treatment of Cancer [Bruxelles] (EORTC), European Cancer Organisation [Bruxelles] (ECCO), Ospedale 'Santa Maria della Misericordia' = University Hospital 'Santa Maria della Misericordia', The University of Sydney, Princess Alexandra Hospital, Brisbane, University of Queensland [Brisbane], Centre Léon Bérard [Lyon], Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Edith Cowan University (ECU), Universitat de Barcelona (UB), The Christie NHS Foundation Trust [Manchester, Royaume-Uni], Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology (MCMCC), Radboud University Medical Center [Nijmegen], Washington University School of Medicine in St. Louis, Washington University in Saint Louis (WUSTL), University Hospital of Siena, Amsterdam UMC - Amsterdam University Medical Center, Hôpital de la Timone [CHU - APHM] (TIMONE), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hannover Medical School [Hannover] (MHH), Centre Hospitalier de l'Université de Montréal (CHUM), Université de Montréal (UdeM), Merck & Co. Inc, AP-HP. Université Paris Saclay, Institut Gustave Roussy (IGR), University Medical Center [Utrecht], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université de Montpellier (UM), Merck Sharp & Dohme., and Guided Treatment in Optimal Selected Cancer Patients (GUTS)

Subjects
Male, Skin Neoplasms, Medizin, Skin Neoplasms / drug therapy, Pembrolizumab, law.invention, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], MESH: Aged, 80 and over, 0302 clinical medicine, Melanoma / pathology, Randomized controlled trial, law, Monoclonal, 80 and over, Clinical endpoint, MESH: Double-Blind Method, 030212 general & internal medicine, Humanized, Melanoma, MESH: Aged, ddc:616, Aged, 80 and over, education.field_of_study, MESH: Middle Aged, Antibodies, Monoclonal, Humanized, Neoplasm Staging, Quality of Life, Double-Blind Method, Adult, Aged, Middle aged, Humans [MeSH], Hazard ratio, MESH: Neoplasm Staging, Middle Aged, Oncology, 030220 oncology & carcinogenesis, Female, Humans, medicine.medical_specialty, Melanoma / psychology, Skin Neoplasms / psychology, MESH: Melanoma, Antibodies, Monoclonal, Humanized / therapeutic use, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, Placebo, Antibodies, Melanoma / mortality, 03 medical and health sciences, Internal medicine, medicine, Adjuvant therapy, education, Skin Neoplasms / pathology, MESH: Humans, Melanoma / drug therapy, business.industry, MESH: Skin Neoplasms, MESH: Quality of Life, MESH: Adult, Skin Neoplasms / mortality, MESH: Male, Clinical trial, MESH: Antibodies, Monoclonal, Humanized, business, MESH: Female
Abstract

Background: The European Organisation for Research and Treatment of Cancer (EORTC) 1325-MG/KEYNOTE-054 trial in patients with resected, high-risk stage III melanoma demonstrated improved recurrence-free survival with adjuvant pembrolizumab compared with placebo (hazard ratio 0·57 [98·4% CI 0·43-0·74]; pMethods: This double-blind, randomised, controlled, phase 3 trial was done at 123 academic centres and community hospitals across 23 countries. Patients aged 18 years or older with previously untreated histologically confirmed stage IIIA, IIIB, or IIIC resected cutaneous melanoma, and an Eastern Cooperative Oncology Group performance status score of 1 or 0 were eligible. Patients were randomly assigned (1:1) using a central interactive voice-response system on the basis of a minimisation technique stratified for stage and geographic region to receive intravenously 200 mg pembrolizumab or placebo. Treatment was administered every 3 weeks for 1 year, or until disease recurrence, unacceptable toxicity, or death. The primary endpoint of the trial was recurrence-free survival (reported elsewhere). HRQOL was a prespecified exploratory endpoint, with global health/quality of life (GHQ) over 2 years measured by the EORTC QLQ-C30 as the primary analysis. Analyses were done in the intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT02362594, and EudraCT, 2014-004944-37, and long-term follow-up is ongoing.Findings: Between Aug 26, 2015, and Nov 14, 2016, 1019 patients were assigned to pembrolizumab (n=514) or placebo (n=505). Median follow-up was 15·1 months (IQR 12·8-16·9) at the time of this analysis. HRQOL compliance was greater than 90% at baseline, greater than 70% during the first year, and greater than 60% thereafter for both groups. Because of low absolute compliance numbers at later follow-up, the analysis was truncated to week 84. Baseline GHQ scores were similar between groups (77·55 [SD 18·20] in the pembrolizumab group and 76·54 [17·81] in the placebo group) and remained stable over time. The difference in average GHQ score between the two groups over the 2 years was -2·2 points (95% CI -4·3 to -0·2). The difference in average score during treatment was -1·1 points (95% CI -3·2 to 0·9) and the difference in average score after treatment was -2·2 points (-4·8 to 0·4). These differences are within the 5-point clinical relevance threshold for the QLQ-C30 and are therefore clinically non-significant.Interpretation: Pembrolizumab does not result in a clinically significant decrease in HRQOL compared with placebo when given as adjuvant therapy for patients with resected, high-risk stage III melanoma. These results support the use of adjuvant pembrolizumab in this setting. placebo when given as adjuvant therapy for patients with resected, high-risk stage III melanoma. These results support the use of adjuvant pembrolizumab in this setting. placebo when given as adjuvant therapy for patients with resected, high-risk stage III melanoma. These results support the use of adjuvant pembrolizumab in this setting.

Published
2021
Full Text
View/download PDF

39. 1160P Methods of nivolumab administration in advanced melanoma: A comparison of patients’ clinical outcomes treated with flat dose or weight-adjusted dose, FLATIMEL study

Author

Campo le Brun, I., Dalle, S., Mortier, L., Dereure, O., Dalac Rat, S., Dutriaux, C., Leccia, M-T., Legoupil, D., Montaudie, H., De Quatrebarbes, J., Gaudy Marqueste, C., Maubec, E., Saiag, P., Pages, C., Brunet Possenti, F., Granel Brocard, F., Porcher, R., Lefevre, W., Lebbe, C., and Kempf, E.

Published
2023
Full Text
View/download PDF

46. Étude du taux d’anticorps anti-BPAG2, mesuré par technique ELISA, comme biomarqueur des complications gravidiques au cours de la pemphigoïde de la grossesse

Author

Flament, J., primary, Jouen, F., additional, Tancrède-Bohin, E., additional, Oro, S., additional, Picard-Dahan, C., additional, Konstantinou, M.P., additional, Dereure, O., additional, Seta, V., additional, Quereux, G., additional, Prost, C., additional, Bedane, C., additional, Debarbieux, S., additional, Bourgault-Villada, I., additional, Delaporte, E., additional, Lacour, J.-P., additional, Richard, M.-A., additional, Pham-Ledard, A., additional, D’Incan, M., additional, Abasq, C., additional, Duvert-Lehembre, S., additional, Lombart, F., additional, Dupuy, A., additional, Hainaut, E., additional, Dompmartin, A., additional, Leccia, M.-T., additional, Vabres, P., additional, Alcaraz, I., additional, Michel, C., additional, Lagrange, B., additional, Litrowski, N., additional, Estève, E., additional, Machet, L., additional, Martin, L., additional, Del Giudice, P., additional, Fenot, M., additional, Belmondo, T., additional, Morin, F., additional, Tressières, B., additional, Joly, P., additional, and Cordel, N., additional

Published
2020
Full Text
View/download PDF

47. Effets indésirables tardifs des anti-PD1 : étude nationale française multicentrique prospective (MELBASE)

Author

Carlet, C., primary, Dalle, S., additional, Leccia, M.-T., additional, Mortier, L., additional, Dalac-Rat, S., additional, Dutriaux, C., additional, Legoupil, D., additional, Montaudie, H., additional, Dereure, O., additional, De Quatrebarbes, J., additional, Granel-Brocard, F., additional, Le Bouar, M., additional, Charles, J., additional, Brunet-Possenti, F., additional, Dreno, B., additional, Lefevre, W., additional, Allayous, C., additional, Lebbe, C., additional, and Nardin, C., additional

Published
2020
Full Text
View/download PDF

49. Évolution du profil au diagnostic des patients atteints de mélanome de la base nationale RIC-Mel

Author

Varey, E., primary, Nguyen, J.-M., additional, Dalle, S., additional, Dupuy, A., additional, Montaudié, H., additional, Lesage, C., additional, Mortier, L., additional, Skowron, F., additional, Celerier, P., additional, Leccia, M.-T., additional, Dalac-Rat, S., additional, Maubec, E., additional, Meyer, N., additional, Combemale, P., additional, Crickx, B., additional, Zehou, O., additional, Dutriaux, C., additional, Khammari, A., additional, Lebbé, C., additional, and Dréno, B., additional

Published
2020
Full Text
View/download PDF

50. L’indice de masse corporelle est-il réellement prédictif des résultats des thérapies systémiques dans le mélanome métastatique ? Étude multicentrique de la cohorte française MelBase

Author

Di Filippo, Y., primary, Dalle, S., additional, Mortier, L., additional, Dutriaux, C., additional, Dalac, S., additional, Leccia, M.-T., additional, Legoupil, D., additional, Saiag, P., additional, Brunet-Possenti, F., additional, Arnault, J.-P., additional, Maubec, E., additional, Granel-Brocard, F., additional, De Quatrebarbes, J., additional, Aubin, F., additional, Lesimple, T., additional, Stoebner, P., additional, Dupuy, A., additional, Stephan, A.-R., additional, Grob, J.-J., additional, Allayous, C., additional, Lefevre, W., additional, Dereure, O., additional, Lebbé, C., additional, and Montaudié, H., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results